1Department of Pathology, Asan Medical Center, University of Ulsan College Medicine, Seoul, Korea
2Department of Otorhinolaryngology-Head and Neck Surgery, Asan Medical Center, University of Ulsan College Medicine, Seoul, Korea
© 2020 The Korean Society of Pathologists/The Korean Society for Cytopathology
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Ethics Statement
All procedures performed for the current study were approved by the Institutional Review Board (IRB) of Asan Medical Center (Approval No. 2020-0746) in accordance with the 1964 Helsinki Declaration and its later amendments. Formal written informed consent was waived by the IRB.
Author contributions
Conceptualization: KJC. Data curation: KJC, UJ, JSS. Formal Analysis: UJ. Investigation: UJ, KJC. Methodology: KJC. Project administration: UJ, JSS, KJC. Resources: UJ, JSS, KJC, SHC, SYN, SYK. Software: UJ. Supervision: KJC. Validation: KJC. Visualization: UJ. Writing—original draft: UJ. Writing—review & editing: KJC. Approval of final manuscript: all authors.
Conflicts of Interest
J.S.S., a contributing editor of the Journal of Pathology and Translational Medicine, was not involved in the editorial evaluation or decision to publish this article. All remaining authors have declared no conflicts of interest
Funding Statement
No funding to declare.
Primary SCC of salivary gland | Metastatic SCC of salivary gland | |
---|---|---|
Staining | ||
Expression | 8 (100) | 8 (100) |
p53 | ||
Positive | 7 (88) | 5 (63) |
Negative | 1 (12) | 3 (37) |
p16 | ||
Positive | 5 (63) | 6 (75) |
Negative | 3 (37) | 2 (25) |
Androgen receptor | ||
Positive | 2 (25)a | 0 |
Negative | 6 (75) | 8 (100) |
GCDFP-15 | ||
Positive | 1 (12) | 0 |
Negative | 7 (88) | 8 (100) |
c-erb B2 | ||
Positive | 1 (12) | 0 |
Negative | 7 (88) | 8 (100) |
Mucicarmine | ||
Positive | 0 | 0 |
Negative | 8 (100) | 8 (100) |
Case No. | Sex/Age (yr) | Location of tumor | Therapy | Survival (mo) | Smoking Hx (PY) | Previous radiation Hx |
---|---|---|---|---|---|---|
1 | M/71 | Parotid gland | Parotidectomy and adjuvant RT | Expired (32.2) | 45 | None |
2 | M/62 | Parotid gland | Parotidectomy and adjuvant CCRT | Alive (97) | 40 | None |
3 | M/58 | Parotid gland | Parotidectomy and adjuvant RT | Expired (21.7) | 30 | None |
4 | F/62 | Submandibular gland | Excision | Alive (67) | None | None |
5 | M/62 | Parotid gland | Parotidectomy and adjuvant CCRT | Alive (58.7) | 40 | None |
6 | M/65 | Parotid gland | Parotidectomy | Alive (48.7) | 30 | None |
7 | M/62 | Submandibular gland | Excision and adjuvant CCRT | Expired (11) | 20 | None |
8 | F/77 | Submandibular gland | Excision and adjuvant RT | Expired (16.3) | None | None |
Case No. | Sex/Age | Origin site of SCC | Location of metastatic tumor | Therapy for metastatic SCC | Survival after metastasis (mo) | Smoking Hx (PY) | Radiation Hx for original SCC |
---|---|---|---|---|---|---|---|
9 | M/70 | Cheek skin | Parotid gland | Parotidectomy | Expired (9.8) | 50 | None |
10 | F/76 | Preauricular skin | Parotid gland | Parotidectomy and adjuvant RT | Expired (142) | None | None |
11 | M/69 | EAC | Parotid gland | Parotidectomy and adjuvant RT | Expired (16.1) | None | None |
12 | F/75 | Eyelid | Parotid gland | Parotidectomy and adjuvant RT | Expired (98.9) | None | None |
13 | F/57 | Tongue | Parotid gland | Parotidectomy and adjuvant RT | Expired (8.7) | 5 | Present |
14 | M/85 | EAC | Parotid gland | Wide excision | Alive (26.7) | 30 | None |
15 | M/76 | Cheek skin | Parotid gland | Excision and adjuvant RT | Alive (24.2) | 60 | None |
16 | F/45 | Scalp | Parotid gland | Parotidectomy and adjuvant CTx | Alive (24.2) | None | None |
Primary SCC | Metastatic SCC | |
---|---|---|
Keratinization and keratin pearls | Present (6 of 8 cases) | Present (7 of 8 cases) |
Intercellular bridges with large nuclei and eosinophil cytoplasm | Present | Present |
Tumor border | Serrated and pointed | Bosselated and expansile |
Peritumoral inflammation | Abundant | Variable |
Necrosis | Variable | Central tumor necrosis |
Desmoplasia | Abundant | Variable |
Extraparenchymal extension | Present (8 of 8 cases) | Present (7 of 8 cases) |
Ductal involvement | Present (2 of 8 cases) | Absent |
Ductal differentiation | Present (1 of 8 cases) | Absent |
Lymphatic invasion | Abundant (7 of 8 cases) | Variable (4 of 8 cases) |
Vascular invasiona | Present (1 of 8 cases) | Present (1 of 8 cases) |
Lymph node metastasis | Present (5 of 8 cases) | Present (3 of 8 cases) |
Ipsilateral | 4 of 8 cases | 3 of 8 cases |
Bilateral | 1 of 8 cases | None |
Primary SCC of salivary gland | Metastatic SCC of salivary gland | |
---|---|---|
Staining | ||
Expression | 8 (100) | 8 (100) |
p53 | ||
Positive | 7 (88) | 5 (63) |
Negative | 1 (12) | 3 (37) |
p16 | ||
Positive | 5 (63) | 6 (75) |
Negative | 3 (37) | 2 (25) |
Androgen receptor | ||
Positive | 2 (25) |
0 |
Negative | 6 (75) | 8 (100) |
GCDFP-15 | ||
Positive | 1 (12) | 0 |
Negative | 7 (88) | 8 (100) |
c-erb B2 | ||
Positive | 1 (12) | 0 |
Negative | 7 (88) | 8 (100) |
Mucicarmine | ||
Positive | 0 | 0 |
Negative | 8 (100) | 8 (100) |
SCC, squamous cell carcinoma; Hx, history; PY, pack years; M, male; RT, radiotherapy; CCRT, combined chemoradiotherapy; F, female.
SCC, squamous cell carcinoma; Hx, history; PY, pack years; M, male; F, female; RT, radiotherapy; EAC, external auditory canal; CTx, chemotherapy.
The case of vascular invasion was concurrently observed with lymphatic invasion in both primary and metastatic squamous cell carcinomas (SCCs).
Values are presented as number (%). SCC, squamous cell carcinoma; GCDFP-15, gross cystic disease fluid protein 15. One of two cases expressing androgen receptor was found in metastatic tumors of primary SCC in lymph nodes.